Catherine Eckford

1 week ago | europeanpharmaceuticalreview.com | Catherine Eckford

Posted: 29 May 2025 | Catherine Eckford (European Pharmaceutical Review) | The innovative device could improve CAR T cell cancer immunotherapy and facilitate its use as a first-line therapy, research suggests. Research has illustrated a potential new device for harvesting T cells that could improve the cost-effectiveness of manufacturing CAR T-cell therapy and make the cancer immunotherapy more accessible to patients.

1 week ago | europeanpharmaceuticalreview.com | Catherine Eckford

Posted: 28 May 2025 | Catherine Eckford (European Pharmaceutical Review) | The deal will support Eli Lilly and Company to advance non-opioid medicines and expand its pain therapy pipeline. Eli Lilly and Company has agreed to acquire the biotech SiteOne Therapeutics, Inc. Shareholders of SiteOne will be eligible for a total of $1.0 billion in cash. The deal includes the Phase II-ready oral NaV1.8 inhibitor STC-004, which is being evaluated as a chronic pain medicine.

1 week ago | europeanpharmaceuticalreview.com | Catherine Eckford

Posted: 27 May 2025 | Catherine Eckford (European Pharmaceutical Review) | The EMA’s committee has granted positive opinions for ten new treatments, including medicines for oncology indications and rare diseases. The Committee for Medicinal Products for Human Use (CHMP) has recommended ten medicines for approval in its latest meeting. The committee recommended authorisation of three cancer medicines.

1 week ago | europeanpharmaceuticalreview.com | Catherine Eckford

Posted: 26 May 2025 | Catherine Eckford (European Pharmaceutical Review) | The demonstrated safety and efficacy of the aldosterone synthase inhibitor suggest its potential in helping patients with hypertension to reach their blood pressure goal, according to the data. New clinical data suggest potential for the first targeted aldosterone synthase inhibitor to treat uncontrolled or resistant hypertension. Launch-HTN trial is the largest Phase III clinical trial of a novel drug for hypertension.

2 weeks ago | europeanpharmaceuticalreview.com | Catherine Eckford

Posted: 23 May 2025 | Catherine Eckford (European Pharmaceutical Review) | The ocular injection, now granted its third FDA approval, offers a more convenient treatment option for patients with vision loss. The US Food and Drug Administration (FDA) has for the first time approved a continuous delivery treatment shown to maintain the vision of patients with diabetic retinopathy with only a nine-monthly refill required.